Oral Presentation: Encouraging Interim Results at 9 Months from an Open-label Study of Simufilam in Alzheimer’s Disease

Title: SavaDx, a Novel Plasma Biomarker to Detect Alzheimer’s Disease, Confirms Mechanism of Action of Simufilam

Title: “Sumifilam (PTI-125) Significantly Improves Eleven CSF Biomarkers in A Randomized, Placebo-Controlled, One-Month Clinical Trial in Alzheimer’s Disease Patients.”

 

Presentation Type:      Late-Breaking, Oral Presentation (LB21)
Presenter:                     Lindsay H. Burns, PhD, SVP Neuroscience, Cassava Sciences
Date/Time:                   November 7, 2020, 11:10 am EST
Venue:                            Virtual conference